- Home
- Companies
- Laxxon Medical
- Products
- Laxxon Medical - SPID (Screen Printed ...
Laxxon Medical - SPID (Screen Printed Innovative Drug) Technology for Drug Delivery Systems
Laxxon Medical's SPID Technology, also known as Screen Printed Innovative Drug Technology, utilizes advanced additive manufacturing to revolutionize drug delivery systems (DDSs). This patented approach enhances the pharmacokinetic profiles of pharmaceuticals by employing sophisticated geometric internal structures alongside a strategic distribution of active ingredients. Central to SPID Technology’s innovation is its capability to manufacture diverse dosage forms including tablets, films, implants, and transdermal patches, each tailored for optimal drug formulation through novel API combinations. Its engineering allows integration of patient safety features, like QR codes, directly onto drug surfaces, facilitating secure, information-rich pharmaceutical solutions. Furthermore, SPID Technology supports scalable production from clinical trials to mass production, accommodating up to 1.5 million units daily. This cold-process technology augments solubility, reduces side effects, and enables single-dose regimens, offering an impactful stride towards better patient compliance. Overall, it creates opportunities for comprehensive, efficient, and safer pharmaceutical manufacturing.
Efficiency
Improves pharmacokinetics of active pharmaceutical ingredients, improving bioavailability and efficacy
Solubility
Enhances the ability of active pharmaceutical ingredients to dissolve
Side Effects
Reduction of adverse side effects
Patient Adherence
Improvements to patient compliance increase success with therapies
Mass Production
Up to 1.5MM units per day of tablets, film, implants, transdermal patches with novel drug formulations, galenic and novel geometric structures
Cold Process
The cold process reduces the risk of heat-related damages to ingredients and increases the range of applicable APIs and freedom of materials
Range of APIs
Enables a wide range of APIs, including multiple API combinations in a single DDS
Printing Speed
Printing speed is significantly faster than any other pharmaceutical printing process
Single Dosage
Reduction of multiple daily doses to a single dose
Laxxon’s additive manufacturing technology offers a unique combination of benefits ranging from cost advantages and size-independent production streams (same process for clinical samples or mass production) to the improvement of bioavailability and enhancement of solubility.
Increased product volume
SPID®-Technology enables the mass-production of tablets, film, implants, and transdermal patches with novel drug formulations and galenic, through novel geometric structures for multiple API combinations.
Faster, more customized printing
The printing speed is significantly faster than any other alternative pharmaceutical printing process. Each layer of the pill may have different dissolving speeds and layers can be as fine as 10 microns.
Clinical trials to production
Our technology can handle small batch sizes for pre-clinical/ clinical trials as well as mass production.
SPID® (Screen Printed Innovative Drug) Technology is Laxxon’s additive manufacturing process. With our patented technology, we can produce a generation of smart drug delivery systems (DDSs) with tailored pharmacokinetics based on advanced geometric internal structures, heterogeneous distribution of active ingredients, and choice of materials.
Laxxon has both an external pipeline as well as an in-house Advanced Patented Generic pipeline. All products created with our SPID®-Technology manufacturing approach – whether engineered in-house or with an external partner – are patent protected.
Based on our technology partner Exentis Group's proprietary screen printing technology platform, SPID®-Technology is a cutting-edge additive manufacturing technology which enables intelligent pharmaceutical application forms, such as oral, transdermal, and implantable dosages, through geometric shaping and heterogeneous distribution of active pharmaceutical ingredients (APIs). Laxxon's IP is continuously growing, and together with the licensed IP from Exentis Group, consists of 230 patents and patent applications with more than 5,500 patent claims.